Results from US Government-Sponsored Phase 1 Trial of VSV Vaccine Reported
?An early-stage clinical trial of an experimental Ebola vaccine conducted at the National Institutes of Health (NIH) and the Walter Reed Army Institute of Research (WRAIR) found that the vaccine, called VSV-ZEBOV, was safe and elicited robust antibody responses in all 40 of the healthy adults who received it. The most common side effects were injection site pain and transient fever that appeared and resolved within 12 to 36 hours after vaccination. A report describing preliminary results of the NIH-WRAIR study appears online today in The New England Journal of Medicine. The VSV-ZEBOV candidate is one of two experimental Ebola vaccines now being tested in the phase 2/3 PREVAIL clinical trial that is enrolling volunteers in Liberia.
“The ongoing Ebola outbreak in West Africa is unprecedented in scope and duration,” said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. “The outbreak is slowly coming under control, thanks to extraordinary and multi-faceted efforts in the affected nations. However, there still are no licensed specific therapies or vaccines for Ebola. Until a safe and effective vaccine is available, the world will continue to be under-prepared for the next Ebola outbreak.”
Scientists at the Public Health Agency of Canada developed the candidate vaccine. It was licensed to NewLink Genetics Corp. of Ames, Iowa, a company collaborating with Merck & Co. Inc., of Kenilworth, New Jersey, which is responsible for advancing this vaccine towards regulatory approval. The investigational vaccine is based on a genetically modified and attenuated vesicular stomatitis virus (VSV), a virus that mainly affects cattle. In the investigational vaccine, a gene for a VSV protein is replaced with a gene segment from a key protein in the Zaire species of Ebola virus. The vaccine does not contain the whole Ebola virus and therefore cannot infect vaccinated persons with Ebola.
The new report summarizes results of the first 52 volunteers enrolled in the study: 26 at the NIH Clinical Center in Bethesda, Maryland, and 26 at the WRAIR clinic in Silver Spring, Maryland. Six volunteers at each site received a placebo injection of saline solution, and the remaining 40 received the experimental vaccine at either one of two different dosages (2 x107 or 3 x106 in 20 volunteers at each site). The NIH trial was led by NIAID investigators Richard T. Davey, Jr., M.D., and John H. Beigel, M.D., while Jason A. Regules, M.D., and Stephen J. Thomas, M.D., headed the trial at WRAIR.
The candidate vaccine’s ability to stimulate immune responses was assessed by sampling the volunteers’ blood at multiple time points following injection. (The blood sampling schedule differed between the two trial sites.) Of those volunteers tested at 14 days after injection, 93 percent (26 out of 28) of whose who had received vaccine developed antibodies against Zaire species of Ebola virus. Antibodies were detected in the remaining 14 volunteers who had received vaccine by 28 days after injection. Antibody responses were approximately three-fold greater in those who received the higher vaccine dose. This information was available to the designers of the PREVAIL trial and was used to guide the decision to use VSV-ZEBOV at the higher dosage level in that trial.
“The prompt, dose-dependent production of high levels of antibodies following a single injection and the overall favorable safety profile of this vaccine make VSV-ZEBOV a promising candidate that might be particularly useful in outbreak interventions,” said Dr. Davey.
The Latest on: Ebola Vaccine
via Google News
The Latest on: Ebola Vaccine
- Hospital preparedness in N.J., other states undercut by boom-and-bust federal funding after 9/11on May 2, 2020 at 10:01 am
The coronavirus pandemic, which has claimed the lives of more than 64,000 people and sickened at least 9,000 health-care workers in the United States, has again brought into sharp relief the ...
- Boom-and-bust federal funding after 9/11 undercut hospitals' preparedness for pandemicson May 2, 2020 at 8:27 am
Congress awarded Hospital Center millions of dollars to design a new emergency department that would treat mass casualties from a terrorist attack or infectious disease and serve as a model for ...
- From Spanish Flu to Ebola, Here's Looking at Worst Pandemics as Covid-19 Continues to Hammer the Worldon April 30, 2020 at 11:45 pm
The Spanish Flu was caused by an unusually deadly HINI Influenza virus and infected about 500 million, wiping out close to 50 million people, one-third of the world’s population at the time.
- Fauci: Vaccine possible by January, remdesivir shows ‘clear cut’ evidence as treatmenton April 30, 2020 at 9:18 am
There’s new hope in the search for a drug to treat the coronavirus as researchers work toward a vaccine. It’s called remdesivir – a drug in initially intended to ...
- The Latest Updates on 9 Experimental Coronavirus Treatmentson April 27, 2020 at 3:06 pm
Identifying a treatment for the novel coronavirus is perhaps the most vital scientific problem of the moment, aside from a vaccine. Here are some of the most important possible treatments for Covid-19 ...
- Conference Report - I. Investigating New Vaccines: Ebola and HIVon April 24, 2020 at 5:00 pm
Dr. Gary Nabel  of the Vaccine Research Center of the ... followed at week 9, and the animals were challenged with Ebola at week 10. In a shorter protocol, only 1 vaccination at week 0 was ...
- I’m Working 14-Hour Days To Develop The Coronavirus Vaccineon April 22, 2020 at 9:12 am
The alarm is set for 6:30 a.m., I start work at 7:45 and finish in the evening at 9 or 10 p.m. I ... worked on therapeutic vaccine candidates for diseases such as HIV, Ebola, Zika, and HPV.
- We could potentially have a vaccine within 12-18 months, an incredibly short amount of timeon April 19, 2020 at 9:14 pm
This is what we did with the Ebola vaccine, and we will continue to leverage ... Covid-19 could lead to 12.9 million deaths in the 73 Gavi-supported countries, compared with 0.9 million deaths ...
- When Will There Be a Coronavirus Vaccine?on April 15, 2020 at 11:26 pm
By mobilizing labs around the world, a prophylactic Ebola vaccine—rVSV-ZEBOV—was rushed ... 6FnaKE7yv5 — Peter Aldhous (@paldhous) April 9, 2020 The focus of the R&D world is now squarely ...
- The science is challenging. But we should be hopeful for a covid-19 vaccine or drug.on April 14, 2020 at 12:01 pm
Traditionally, it takes years to develop, test and manufacture a vaccine; the one that worked in Congo against Ebola was under development for a decade. These hurdles haven’t changed ...
via Bing News